News
Cytotect®CP found to be safe and effective after allo-HCT
A small retrospective study of 23 transplant patients has confirmed that CMV hyperimmune globulin (Cytotect®CP) is a safe and effective salvage...
News
Liquid biopsies may be the future in managing MM patients
Scientists from the Dana-Farber Cancer Institute and the Broad Institute in Boston, Massachusetts, have shown that in multiple myeloma (MM),...
News
FDA places CTX001 for SCD on clinical hold
The US Food and Drug Administration (FDA) has placed a clinical hold on the investigational new drug application (IND) for CTX001.
News
VF incidence increases significantly in kids after ALL treatment
A 6-year prospective study from the Canadian STOPP investigators revealed that following treatment for acute lymphoblastic leukemia (ALL),...
News
Study of daratumamb with anti-PD-1 antibody in MM discontinued
Janssen is discontinuing the phase 1 MMY2036 study of daratumumab in combination with the anti PD-1 antibody JNJ-63723283 in patients with...
News
FDA grants priority review to gilteritinib for R/R AML
The US Food and Drug Administration (FDA) has granted priority review to gilteritinib for the treatment of adult patients with relapsed or...
News
A closer look at the BK polyomavirus
A detailed image at near-atomic levels of the BK polyomavirus (BKV), which affects kidney and bone marrow transplant patients, is now available...
News
Perioperative rVWF alone sufficient for some VWD patients
GLASGOW—Recombinant von Willebrand factor (rVWF) alone can be sufficient as perioperative management for some patients with severe von Willebrand...
News
FDA clears device for treatment of PE
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the FlowTriever System for the treatment of pulmonary embolism (PE)....
News
Emicizumab controls bleeding regardless of inhibitors
GLASGOW—Emicizumab prophylaxis provides “clinically meaningful” control of bleeding whether or not patients have factor VIII inhibitors, according...
News
Gene therapy reduces ABR, AIR in hemophilia B
GLASGOW—New research suggests the gene therapy SPK-9001 can reduce bleeding and the need for factor IX infusions in patients with hemophilia B....
News
N9-GP has better PK profile than rFIXFc, team says
GLASGOW—Nonacog beta pegol (N9-GP) has a better pharmacokinetic (PK) profile than recombinant factor IX-Fc fusion protein (rFIXFc), according to...
News
Therapy can extend half-life of FVIII
GLASGOW—Preliminary data suggest an investigational therapy can extend the half-life of factor VIII (FVIII) in patients with severe hemophilia A...
News
Early infection could prevent ALL, doc says
Childhood acute lymphoblastic leukemia (ALL) may be preventable, according to a researcher. Mel Greaves, PhD, of The Institute of Cancer Research...
News
Emicizumab reduces bleeding in hemophilia A
GLASGOW—Final results from the HAVEN 3 study suggest emicizumab prophylaxis can reduce bleeding in hemophilia A patients without factor VIII...